ReviewOpen life sciences2021
Diabetes and COVID-19.
Review in Open life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Comorbidities increase the severity of COVID-19: an analysis and epidemiological study conducted in Algeria.The Libyan journal of medicine · 2026Article
- Neutrophil-Linked Inflammatory Mechanisms and Biomarkers in Diabetic Microvascular Complications.Diabetes & metabolism journal · 2026Review
- Association Between Diabetes Mellitus-Tuberculosis and the Generation of Drug Resistance.Microorganisms · 2024Review
- Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism.Biomedicines · 2024Review
- Article
- Article
- Treating COVID-19 with Medicinal Plants: Is It Even Conceivable? A Comprehensive Review.Viruses · 2024Review
- Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis.Experimental and therapeutic medicine · 2023Article
- The Potential of Collagen Treatment for Comorbid Diseases.Polymers · 2023Review
- Article
- Prediction of in-hospital mortality rate in COVID-19 patients with diabetes mellitus using machine learning methods.Journal of diabetes and metabolic disorders · 2023Article
- The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions.Frontiers in immunology · 2023Review
- Persistence and occurrence of SARS-CoV-2 in water and wastewater environments: a review of the current literature.Environmental science and pollution research international · 2022Review
- Impact of COVID-19 on Patients with Diabetes Standard of Care in the Jazan Region, Saudi Arabia.Materia socio-medica · 2022Article
- Sustained seropositivity up to 20.5 months after COVID-19.BMC medicine · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Review
- Article
- RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.Pathogens (Basel, Switzerland) · 2022Review
- The Concern of COVID-19 Vaccine Safety Is behind Its Low Uptake among Patients with Diabetes Mellitus in Sudan.Vaccines · 2022Article
- Spatio-temporal modeling of COVID-19 prevalence and mortality using artificial neural network algorithms.Spatial and spatio-temporal epidemiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several factors are linked with a higher risk of mortality from Coronavirus disease-19 (COVID-19), including male gender, increased age, hypertension, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Hyperglycemic COVID-19 patients have severe clinical problems, increased ICU admittance, machine-driven ventilation, and a substantial rise in inflammatory markers. Among all patients, those with diabetes or hyperglycemia have a two- to four-fold increase in mortality and severity of COVID-19 than those without diabetes. The primary cause of mortality in COVID-19 patients with diabetes is compromised immune response to viral infections. Increased blood sugar level probably affects intracellular degradation of bacteria, neutrophil chemotaxis, and phagocytosis, thus improving viral binding affinity and entry and decreasing virus clearance. In addition, it has significant effects on the proteins by inducing glycosylation and altering the composition of complements, and glycosylation renders cells susceptible to viral inflammation and damage. The treatment of COVID-19 in patients with diabetes requires an integrated team approach to minimize the risk of medical complications and mortality. Moreover, physicians should adopt proactive strategies to care for persons with comorbidities. This strategy would help reduce the frequency of complications and mortality among patients and load on the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.